Non Regulatory Announcement

Oct 20, 2011

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

RNS Number : 5038Q
Advanced Medical Solutions Grp PLC
20 October 2011

For immediate release: 20 October 2011 


Advanced Medical Solutions Group plc

(“AMS” or the “Group”)


Results of US pilot study on LiquiBand®

effectiveness in closing scalp lacerations 


Winsford, UK: Researchers from the University of Florida-Jacksonville, College of Medicine presented the results of a pilot study utilising LiquiBand® topical skin adhesive at the American College of Emergency Physicians (ACEP) Scientific Assembly in San Francisco, October 15-18, 2011. The study demonstrated the effectiveness of LiquiBand® in the closure of scalp lacerations.


Dermal adhesives are commonly used for facial wound repairs but are rarely used in the US for scalp wounds. LiquiBand® is a fast polymerizing, medical grade adhesive (cyanoacrylate) that has been successfully used in Europe for topical skin closure, including closing scalp wounds, for more than ten years. This is, however, the first study in the US that specifically addresses the use of dermal adhesives on scalp wounds. Emergency physicians measured ease-of-use, closure time, wound appearance and complications, while patients assessed wound appearance post-closure and pain levels during application.


The physicians involved in the study found that LiquiBand® treated scalp wounds very effectively, giving an average score of 4.67 out of 5. Patients reported very low pain scores during the procedures, and all parties indicated that they would use LiquiBand® again rather than traditiional staples or sutures.


Commenting on this announcement, Chris Meredith, Chief Executive Officer of AMS commented: “This small pilot study clearly supports what we already knew, namely that LiquiBand® can be used safely for rapid closure of simple scalp lacerations with minimal pain and excellent cosmetic outcomes. However, the key aspect of this study is that it is the first of its kind in the US. The results pave the way for a larger prospective study to be undertaken, but we believe that the high levels of reported physician and patient satisfaction should give direct support to the already encouraging marketing initiatives of our partners in that key market.”


ends –


Advanced Medical Solutions Group plc

Tel: +44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Mary Tavener, Group Finance Director

Paul Hodge, Global Marketing Manager

Tel: +1 404 695 9099

Tavistock Communications

Tel: +44 (0) 20 7920 3150

John West / Chris Munden / Andrew Dunn


Notes to Editors:


About Advanced Medical Solutions Group plc – see


Advanced Medical Solutions Group is a global business providing innovative products and brands in the areas of accelerating healing and managing wounds, minimising adverse surgical outcomes and sealing and closing tissue. These products are sold in countries across the globe either directly or through a number of strategic partners and distributors.


AMS’ advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids, provide an optimal environment for healing to occur and, in the case of silver alginates, include a safe and effective broad-spectrum anti-microbial agent for infection control.


AMS’ wound closure and sealants products are based on cyanoacrylate adhesive (“superglue”) technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.


For further information on LiquiBand, see


This information is provided by RNS
The company news service from the London Stock Exchange




For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.